CYP19A1 and endometriosis: GnRH agonist or synthetic progestins effectively down‐regulate ovarian estradiol biosynthesis and have very little impact on extraovarian estrogens.7 In this context, third generation aromatase inhibitors such as anastrozole have been investigated as therapeutic option for women with endometriosis.